Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obexelimab - Zenas Biopharma

Next Previous
Drug Profile

Obexelimab - Zenas Biopharma

Alternative Names: AMG 729; Humanised Fc-engineered monoclonal antibody against CD19 - Xencor; XmAb® 5871

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xencor
  • Developer Xencor; Zenas BioPharma
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Autoimmune disorders; Autoimmune haemolytic anaemia
  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 10 Nov 2023 Pharmacokinetics and pharmacodynamics data from clinical trial in Rheumatoid arthritia presented at the ACR Convergence 2023 (ACR-ARP-2023 2023)
  • 10 Nov 2023 Efficacy data from phase II trial in Autoimmune disorders presented at the ACR Convergence 2023
  • 25 Sep 2023 Phase-III clinical trials in Autoimmune haemolytic anaemia (Treatment-experienced) in United Kingdom, Spain, Spain, Poland, Italy (SC) (NCT05786573)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top